Pomalidomide plus Low-Dose Dexamethasone plus Daratumumab in Relapsed and/or Refractory Multiple Myeloma after Lenalidomide-Based Treatment Failure

被引：0

作者：

Siegel, David S. ^{[1
,2
]}

Schiller, Gary J. ^{[3
]}

Samaras, Christy J. ^{[4
]}

Sebag, Michael ^{[5
]}

Berdeja, Jesus G. ^{[6
]}

Ganguly, Siddhartha ^{[7
]}

Matous, Jeffrey V. ^{[8
]}

Song, Kevin ^{[9
]}

Seet, Christopher S. ^{[10
]}

Talamo, Giampaolo ^{[11
]}

Acosta-Rivera, Mirelis ^{[12
]}

Bar, Michael ^{[13
]}

Quick, Donald P. ^{[14
]}

Anz, Bertrand ^{[15
]}

Fonseca, Gustavo ^{[16
]}

Reece, Donna ^{[17
]}

Agarwal, Amit ^{[18
]}

Chung, Weiyuan ^{[18
]}

Zafar, Faiza ^{[18
]}

Bahlis, Nizar ^{[19
]}

机构：

[1] Hackensack Univ, Med Ctr, John Theurer Canc Ctr, Myeloma Div, Hackensack, NJ USA

[2] Hackensack Univ, Med Ctr, John Theurer Canc Ctr, Lymphoma Div, Hackensack, NJ USA

[3] UCLA, David Geffen Sch Med, Los Angeles, CA USA

[4] Cleveland Clin, Taussig Canc Inst, Dept Hematol & Med Oncol, Cleveland, OH USA

[5] McGill Univ, Hlth Ctr, Montreal, PQ, Canada

[6] Sarah Cannon Res Inst, Nashville, TN USA

[7] Univ Kansas, Ctr Canc, Fairway, KS USA

[8] Colorado Blood Canc Inst, Denver, CO USA

[9] Vancouver Gen Hosp, Vancouver, BC, Canada

[10] UCLA, Med Ctr, Los Angeles, CA USA

[11] Penn State Hershey Canc Inst, Hershey, PA USA

[12] Fdn Invest, San Juan, PR USA

[13] Stamford Hosp, Stamford, CT USA

[14] Joe Arrington Canc Res Treatment Ctr, Lubbock, TX USA

[15] Tennessee Oncol, Chattanooga, TN USA

[16] Florida Canc Specialists, St Petersburg, FL USA

[17] Princess Margaret Canc Ctr, Toronto, ON, Canada

[18] Celgene Corp, Summit, NJ USA

[19] Univ Calgary, Calgary, AB, Canada

来源：

BLOOD | 2018年 / 132卷

关键词：

D O I：

10.1182/blood-2018-99-111920

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

3271

引用

页数：4

共 50 条

[21] Impact of Lenalidomide Plus Low-Dose Dexamethasone Treatment on Immune Cell Populations of the Patients with Refractory/Relapsed Multiple Myeloma
Lee, Sung-Eun
Lim, Ji-Young
Ryu, Da-Bin
Kim, Tae Woo
Jeon, Young-Woo
Yoon, Jae-Ho
Cho, Byung-Sik
Eom, Ki-Seong
Kim, Yoo-Jin
Kim, Hee-Je
Lee, Seok
Cho, Seok-Goo
Kim, Dong-Wook
Lee, Jong Wook
Min, Woo-Sung
Min, Chang-Ki
BLOOD, 2015, 126 (23)
[22] Selinexor Plus Pomalidomide and Low Dose Dexamethasone (SPd) in Patients with Relapsed or Refractory Multiple Myeloma
Chen, Christine I.
Sutherland, Heather J.
Kotb, Rami
Sebag, Michael
White, Darrell J.
Bensinger, William
Gasparetto, Cristina J.
Leblanc, Richard
Venner, Christopher P.
Lentzsch, Suzanne
Schiller, Gary J.
Lipe, Brea
Del Col, Aldo
Shah, Jatin J.
Jeha, Jacqueline
Saint-Martin, Jean-Richard
Kauffman, Michael G.
Shacham, Sharon
Bahlis, Nizar
BLOOD, 2018, 132
[23] A STATISTICAL COMPARISON OF THE EFFICACY AND SAFETY OF LOW-DOSE LENALIDOMIDE plus LOW- DOSE DEXAMETHASONE WITH FULL-DOSE LENALIDOMIDE plus DEXAMETHASONE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM)
Quach, H.
Fernyhough, L.
Henderson, R.
Corbett, G.
Honemann, D.
Blacklock, H.
Browett, P.
Link, E.
Cowan, L.
Li, J.
Swern, A.
Hussein, M.
Lynch, K.
Dimopoulos, M.
Prince, M.
HAEMATOLOGICA, 2012, 97 : 350 - 351
[24] Pembrolizumab, pomalidomide, and low-dose dexamethasone for relapsed/refractory multiple myeloma
Badros, Ashraf
Hyjek, Elizabeth
Ma, Ning
Lesokhin, Alexander
Dogan, Ahmet
Rapoport, Aaron P.
Kocoglu, Mehmet
Lederer, Emily
Philip, Sunita
Milliron, Todd
Dell, Cameron
Goloubeva, Olga
Singh, Zeba
BLOOD, 2017, 130 (10) : 1189 - 1197
[25] Pomalidomide Plus Low-Dose Dexamethasone (POM plus LoDEX) for Relapsed and Refractory Multiple Myeloma (RRMM): Results from a Pharmacoeconomic Evaluation
Schey, Steve
Dhanasiri, Sujith
Lee, Dawn
Sternas, Lars
Yu, Xin
Zaki, Mohamed H.
Elvidge, Jamie
O'Dwyer, Michael
BLOOD, 2014, 124 (21)
[26] Impact of depression on adherence to lenalidomide plus low-dose dexamethasone in patients with relapsed or refractory myeloma
Seok Jin Kim
Danbee Kang
Yong Park
Yeung-Chul Mun
Kihyun Kim
Jin Seok Kim
Chang-Ki Min
Juhee Cho
Supportive Care in Cancer, 2021, 29 : 4969 - 4977
[27] Impact of depression on adherence to lenalidomide plus low-dose dexamethasone in patients with relapsed or refractory myeloma
Kim, Seok Jin
Kang, Danbee
Park, Yong
Mun, Yeung-Chul
Kim, Kihyun
Kim, Jin Seok
Min, Chang-Ki
Cho, Juhee
SUPPORTIVE CARE IN CANCER, 2021, 29 (09) : 4969 - 4977
[28] Pomalidomide (CC4047) Plus Low-Dose Dexamethasone As Therapy for Relapsed Multiple Myeloma
Lacy, Martha Q.
Hayman, Suzanne R.
Gertz, Morie A.
Dispenzieri, Angela
Buadi, Francis
Kumar, Shaji
Greipp, Philip R.
Lust, John A.
Russell, Stephen J.
Dingli, David
Kyle, Robert A.
Fonseca, Rafael
Bergsagel, P. Leif
Roy, Vivek
Mikhael, Joseph R.
Stewart, A. Keith
Laumann, Kristina
Allred, Jacob B.
Mandrekar, Sumithra J.
Rajkumar, S. Vincent
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (30) : 5008 - 5014
[29] Immune Profiling of Relapsed or Refractory Multiple Myeloma Patients Treated with Pomalidomide and Low-Dose Dexamethasone in Combination with Daratumumab
Pierceall, William E.
Bahlis, Nizar
Siegel, David S.
Schiller, Gary J.
Samaras, Christy J.
Sebag, Michael
Berdeja, Jesus G.
Ganguly, Siddhartha
Matous, Jeffrey V.
Song, Kevin
Seet, Christopher S.
Talamo, Giampaolo
Srinivas, Shanti
Acosta-Rivera, Mirelis
Bar, Michael
Quick, Donald P.
Anz, Bertrand
Fonseca, Gustavo
Reece, Donna
Chung, Weiyuan
Serbina, Natalya
Zafar, Faiza
Agarwal, Amit
Thakurta, Anjan
BLOOD, 2018, 132
[30] Investigating Efficacy, Safety, and Biomarkers in a Phase 2 Trial of Pomalidomide plus Low-Dose Dexamethasone (POM plus LoDEX) Following Second-Line Lenalidomide-Based Therapy (Tx) in Relapsed or Refractory Multiple Myeloma (RRMM)
Siegel, David S.
Schiller, Gary
Song, Kevin
Agajanian, Richy
Stockerl-Goldstein, Keith
Kaya, Hakan
Sebag, Michael
Reu, Frederic J.
Mouro, Jorge
Sturniolo, Michael
Srinivasan, Shankar
Thakurta, Anjan
Nagarwala, Yasir
Bahlis, Nizar J.
BLOOD, 2015, 126 (23)

← 1 2 3 4 5 →